Please login to the form below
checkpoint inhibitor
This page shows the latest checkpoint inhibitor news and features for those working in and with pharma, biotech and healthcare.
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
The US Food and Drug Administration (FDA) has cleared checkpoint inhibitor Keytruda (pembrolizumab) plus tyrosine kinase inhibitor (TKI) Lenvima (lenvatinib) for the treatment of patients with advanced endometrial cancer that is
Latest news
-
Merck & Co withdraws Keytruda’s US approval in third-line stomach cancer
However, the checkpoint inhibitor was unable to demonstrate an overall survival benefit for patients with recurrent locally-advanced or metastatic gastric or gastroesophageal junction cancer when used as a third-line
-
Merck’s Keytruda improves outcomes for metastatic cervical cancer patients
Merck – known as MSD outside the US and Canada – has revealed positive results for its checkpoint inhibitor Keytruda in patients with persistent, recurrent or metastatic cervical cancer. ... In March, Sanofi and Regeneron revealed positive data for
-
Roche's Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients
Tecentriq is currently approved for the front-line treatment of small cell lung cancer (SCLC), a market where the checkpoint inhibitor has been able to carve a niche away from the
-
Merck & Co reveals plans for women’s health spinoff Organon
namely blockbuster checkpoint inhibitor Keytruda (pembrolizumab) – but will also “enable necessary investments”.
-
Pfizer’s COVID-19 vaccine yields $3.5bn in first quarter sales
indications. Sales for Pfizer tyrosine kinase inhibitor (TKI) Inlyta were also up by 34% operationally, following increased demand in the US and approvals in 2019 for a combination of the drug ... plus Merck &Co’s checkpoint inhibitor Keytruda for the
More from news
Approximately 11 fully matching, plus 214 partially matching documents found.
Latest Intelligence
-
Surviving cancer: a new era for patients
Immune checkpoint inhibitors. Immune (T) cells exhibit proteins that can turn an immune response on or off, called checkpoint proteins. ... Several checkpoint inhibitor drugs have been developed showing strong event- free survival and PFS rates, opening
-
Can protein degraders unlock ‘undruggable’ drug targets?
These compounds could be used to tackle resistance to kinase inhibitor drugs, for example. ... The lead project in that partnership is an inhibitor of CBL-B, an immune checkpoint that is still in preclinical development and will migrate to Bristol-Myers
-
20 for 2020 – Five pharma companies to watch
checkpoint inhibitor Imfinzi such as the POSEIDON trial in first-line NSCLC, are key newsflow events this year. ... Trial results for Opdivo alongside CTLA4 checkpoint inhibitor Yervoy (ipilimumab) are one key element of that, particularly better
-
Immuno-oncology in 2019: the rapid evolution continues
cells to identify and fight cancer: the PD-1 and PD-L1 checkpoint inhibitor immunotherapies. ... 50%. The true figure for patients treated with checkpoint inhibitor monotherapy achieving durable and meaningful clinical responses is in fact nearer 20%.
-
Drug launches to watch in 2019
Merck/MSD looks to have gained a dominant position in checkpoint inhibitor immuno-oncology (IO) with Keytruda – but there remains room for growth in the market via new IO agents. ... t the only oral JAK inhibitor developer with its eye on that
More from intelligence
Approximately 0 fully matching, plus 17 partially matching documents found.
Latest appointments
-
Merck’s R&D chief Roger Perlmutter heads for the exit as Dean Li takes the helm
This includes the approval of Merck’s checkpoint inhibitor Keytruda (pembrolizumab), which has been approved in over 25 indications across 16 tumour types.
-
New hires at Crescendo, Healx and Galecto
oncology. Prior to Crescendo, Hashimoto (pictured below, right) led the clinical development of a checkpoint inhibitor in renal cell carcinoma at Roche, and held responsibility for multiple.
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Parachuting Behind Enemy Lines: OncoSec’s Attack on Visceral Tumors via Its New Visceral Lesion Applicator (VLA)
Checkpoint inhibitor-refractory disease represents a growing population and an emerging therapeutic challenge. ... trocar. Further, TAVO has already proven to show robust efficacy in difficult-to-treat patient populations, including metastatic melanoma
-
Highlights in haematologic malignancy from ASH 2018
Initial findings from small groups of patients suggest CD19-directed CAR T-cell therapy, plus ibrutinib or a checkpoint inhibitor, can enhance responses and/or reduce toxicity in difficult-to-treat
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Vaccines writer – career opportunity to move into medcomms from ...
-
Highly competitive salary
- Senior Account Exec > CSD – Medical Communications – UK, Lond...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Principal Medical Writer, MRNA/ Covid 19, Medical Communications...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Account Supervisor – Leading Healthcare Advertising Agency – New...
-
Highly Competitive Salary, Bonus &Benefits
- Scientific Director, MRNA/ Covid 19, Medical Communications, UK
-
Six figure salary
- Senior Medical Writer – Creative Healthcare Advertising – New Yo...
-
Highly Competitive Salary, Bonus &Benefits
- Medical Writers > Scientific Directors – Medical Communicatio...
-
Highly Competitive Salary, Bonus &Benefits
- First trial of a vaccine against Alzheimer’s launches
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- US government to pay $5.3bn for Pfizer‘s Paxlovid
- Gilead to pay $745m for three oncology programmes from Arcus Biosciences
- Merck’s anti-COVID drug molnupiravir moves to phase 3 for prevention
- Roche to present new data for its drug Polivy at the American Society of Hematology’s annual meeting
- Lucid Group: Orange the World
- First trial of a vaccine against Alzheimer’s launches
- New COVID variant causing concern
- PMEA 2021: A Celebration of Excellence in Patient Engagement
- From Academics to Entrepreneurship: How Tech is Revolutionizing the Diagnostics Landscape
- Impetus Digital wins Canada’s Most Admired Corporate Cultures Awards 2021
- Results for Merck’s oral cholesterol inhibitor show it to be ‘highly effective’
- Biogen’s Aduhelm unlikely to get approval in Europe
- Gilead’s Trodelvy approved for triple-negative breast cancer in Europe
- The pandemic preparedness paradox
- First trial of a vaccine against Alzheimer’s launches
- Good NICE news for Pfizer, but Dendreon drug rejected
PMHub
CSafe Global
CSafe Global is the only global provider of a full line of cold chain solutions and is the world’s largest...
Latest intelligence
- Webinar:
- Securing a future for telehealth with immersive market research insights...
- Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
- How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
- Six ways to improve diversity in clinical trials
- Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...
